Florham Park, NJ, August 2, 2021
Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Ketoconazole Foam, 2%, generic to Extina®.
“This is an exciting day for Xiromed as we launch our first foam product in the US market. Xiromed is focused on expanding the range of dosage forms offered in our portfolio, and the launch of Ketoconazole Foam, 2% demonstrates our commitment to expansion into a wide variety of dosage forms, in order to drive value for our customers,” commented Xiromed CEO, Narasimhan Mani.
Annual market sales for Extina® and its generics for the twelve month period ending April, 2021 were $6.2 million, according to IQVIA™. Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/